Inhibikase Therapeutics, Inc..
IKT.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for Parkinson's disease and related disorders. Their primary focus is on small molecule kinase inhibitors that target protein kinases involved in intracellular signaling pathways. The compa...Show More
Better Health for All
0
No evidence available to assess Inhibikase Therapeutics, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
No evidence available to assess Inhibikase Therapeutics, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence available to assess Inhibikase Therapeutics, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Inhibikase Therapeutics, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-40
The company has a formal whistleblower policy that includes an anonymous reporting hotline.
1
It also has an anti-corruption policy that explicitly addresses FCPA compliance, prohibits bribes, kickbacks, and inappropriate gifts to foreign officials, and includes specific guidelines for business gifts and entertainment.
2
However, the available evidence does not provide details on independent investigation processes for whistleblower reports, nor does it mention the frequency or effectiveness metrics of anti-corruption training.
Kind to Animals
0
No specific, concrete data points regarding Inhibikase Therapeutics' animal welfare practices, animal testing policies, or related initiatives were found in the provided articles. The articles focus on regulatory meetings, financial performance, and drug development milestones, without mentioning any details relevant to the 'Kind to Animals' ethical value.
No War, No Weapons
0
Inhibikase Therapeutics is a clinical-stage pharmaceutical company focused on developing therapies for Parkinson's disease and leukemia
1
,
2
. The company's activities are centered around research, clinical trials, and potential commercialization of pharmaceutical products
3
,
4
. There is no indication that their products or research have direct applications in weapons development, military technology, or conflict facilitation
5
,
6
. Therefore, based on the available evidence, the company's operations are considered neutral in relation to the "No War, No Weapons" value
7
,
8
. Insufficient evidence exists to provide a positive or negative score.
Planet-Friendly Business
-40
In 2023, the company's total greenhouse gas emissions were 1,045 metric tons CO2e, representing a 16.4% reduction from 2022.
1
The company has a carbon neutrality goal set for 2030.
2
No environmental compliance violations were reported in the 2024 annual report or the PESTLE analysis.
3
Respect for Cultures & Communities
0
No evidence available to assess Inhibikase Therapeutics, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No evidence available to assess Inhibikase Therapeutics, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No evidence was found in the provided articles regarding Inhibikase Therapeutics, Inc.'s performance on any of the Zero Waste & Sustainable Products KPIs.
1
The articles focus on financial results and operational highlights, explicitly stating that no relevant data for this category is present.
2